Ikena Oncology Inc. (IKNA): Multiplikator P/S

Simbol lan logo merek ikenaoncology.com (IKNA)

The P/S chart confirms the financial stability of Ikena Oncology, Inc. (IKNA), whose cash reserves fully cover development costs. The current 104.50 reflects the state of the metric amid fierce competition with pharma market behemoths. The absence of profit-generating products forces the company to systematically spend capital on clinical trials, creating a certain degree of operational inertia.

IKNA Rasio rega marang pendapatan Ikena (04.07.2022 - 07.03.2025)

Ikena Oncology Inc. (IKNA) - rincian metrik lan laporan keuangan

- rega lan prakiraan konsensus rega:
Analisis fundamental perusahaan:IKNA - Ikena Oncology, Inc.
Produk mawa merek Ikena Oncology

To objectively assess the fundamental value of Ikena Oncology, Inc. (IKNA), investors must analyze the ratio of market capitalization to annual sales. When analyzing the company's current P/S, it should be noted that this ratio measures the market premium to revenue, where rising values signal expectations of breakthrough successes in joint cancer drug developments with academic centers.

Pesaing Ikena Oncology, Inc.

ONC - Rega marang dodolan|Multiplikator P/S HALO (Halozyme Therapeutics, Inc.)|Revolution Medicines (RVMD) - Rega marang dodolan|ascentage.com - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan CGON (cgoncology.com)|URGN: Multiplikator P/S|Bicara Therapeutics Inc (BCAX) - Multiplikator P/S|Rasio rega marang pendapatan personalis.com|Kapitalisasi marang pendapatan Erasca Corp (ERAS)|Kapitalisasi marang pendapatan DCTH (Delcath)|Koefisien rega marang pendapatan Y-mAbs Therapeutics, Inc.|Multiplikator P/S AURA (Aura Biosciences Inc)|Rasio kapitalisasi pasar marang pendapatan CADL|ARAY: Kapitalisasi marang pendapatan|Koefisien rega marang pendapatan sellaslifesciences.com SLS|ACTU (Actuate Therapeutics, Inc) - Kapitalisasi marang pendapatan|Rasio kapitalisasi marang pendapatan CTOR|Rasio rega marang pendapatan TuHURA Biosciences Inc.|TARA: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Fate Therapeutics (FATE)|Koefisien rega marang pendapatan Aadi Bioscience|Rasio rega marang pendapatan TScan Therapeutics Inc TCRX|CSBR: Rasio kapitalisasi marang pendapatan|XBIT: Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan CVM (cel-sci.com)|OSTX: Multiplikator P/S|Rega marang dodolan Radiopharm Theranostics Ltd (RADX)|ARTV (Artiva) - Multiplikator P/S|Rasio kapitalisasi marang pendapatan ANL (Adlai Nortye)|Rasio rega marang pendapatan Veru Pharma (VERU)|Multiplikator P/S Tempest Tx (TPST)|Rasio rega marang pendapatan xiliotx.com XLO|Enochian BioSciences - Rasio rega marang pendapatan|Mural Oncology - Multiplikator P/S|KAPA - Multiplikator P/S|OnKure Therapeutics Inc (OKUR) - Rasio rega marang pendapatan|Kapitalisasi marang pendapatan CytoMed|Rasio rega marang pendapatan curis.com|Kapitalisasi marang pendapatan Apollomics, Inc. (APLM)|Multiplikator P/S THAR|Advanced Biomed Corp - Rasio kapitalisasi marang pendapatan|Rasio rega marang pendapatan Genprex GNPX|Koefisien rega marang pendapatan Calidi Bio (CLDI)|sunshinebiopharma.com - Multiplikator P/S|Rega marang dodolan xeneticbio.com|salariuspharma.com (SLRX) - Rasio rega marang pendapatan|Purple Biotech Ltd. - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan AON|Multiplikator P/S BeiGene Ltd.|Rasio rega marang pendapatan Checkpoint Therapeutics, Inc. (CKPT)|Kapitalisasi marang pendapatan Elevation Oncology, Inc. ELEV|Multiplikator P/S ICAD (iCAD Inc.)|Rasio kapitalisasi pasar marang pendapatan NTBL|Viracta Therapeutics, Inc. - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan MOR (MorphoSys Inc)|NAYA (NAYA Biosciences Inc) - Kapitalisasi marang pendapatan|Kapitalisasi marang pendapatan Ascentage Pharma Group Ltd